IdentificationGeneric Name(1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-PyrrolidineDrugBank Accession NumberDB02367BackgroundNot AvailableTypeSmall MoleculeGroupsExperimentalStructure


3DDownload MOLSDF3D-SDFPDBSMILESInChI


 Similar StructuresStructure for (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine (DB02367)× CloseWeightAverage: 435.516 Monoisotopic: 435.113391549 Chemical FormulaC16H25N3O7S2SynonymsNot AvailablePharmacologyIndicationNot AvailableReduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, & validate predictive machine-learning models with structured datasets.See howContraindications & Blackbox WarningsAvoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Learn more  Avoid life-threatening adverse drug events & improve clinical decision support.Learn morePharmacodynamicsNot AvailableMechanism of actionTargetActionsOrganismUStromelysin-1Not AvailableHumansAbsorptionNot AvailableVolume of distributionNot AvailableProtein bindingNot AvailableMetabolismNot AvailableRoute of eliminationNot AvailableHalf-lifeNot AvailableClearanceNot AvailableAdverse EffectsImprove decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Learn more  Improve decision support & research outcomes with our structured adverse effects data.Learn moreToxicityNot AvailablePathwaysNot AvailablePharmacogenomic Effects/ADRs 


Not AvailableInteractionsDrug Interactions 


This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. Not AvailableFood InteractionsNot AvailableCategoriesDrug CategoriesNot AvailableChemical TaxonomyProvided by ClassyfireDescriptionThis compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.KingdomOrganic compoundsSuper ClassOrganic acids and derivativesClassCarboxylic acids and derivativesSub ClassAmino acids, peptides, and analoguesDirect ParentProline and derivativesAlternative ParentsAlpha amino acid amides / Benzenesulfonamides / Benzenesulfonyl compounds / Pyrrolidinecarboxamides / Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Organosulfonamides / Organic sulfonamides / Aminosulfonyl compounds / Hydroxamic acids / Azacyclic compounds / Hydrocarbon derivatives / Organopnictogen compounds / Organic oxides / Organonitrogen compounds / Carbonyl compounds


 show 7 moreSubstituentsAlkyl aryl ether / Alpha-amino acid amide / Aminosulfonyl compound / Aromatic heteromonocyclic compound / Azacycle / Benzenesulfonamide / Benzenesulfonyl group / Benzenoid / Carbonyl group / Ether / Hydrocarbon derivative / Hydroxamic acid / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organic sulfonic acid amide / Organic sulfonic acid or derivatives / Organoheterocyclic compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Organosulfonic acid amide / Organosulfonic acid or derivatives / Organosulfur compound / Phenol ether / Phenoxy compound / Proline or derivatives / Pyrrolidine / Pyrrolidine carboxylic acid or derivatives / Pyrrolidine-2-carboxamide / Sulfonyl


 show 22 moreMolecular FrameworkAromatic heteromonocyclic compoundsExternal Descriptorssulfonamide, N-acylpyrrolidine, D-proline derivative, pyrrolidinehydroxamic acid (CHEBI:39531) Affected organismsNot AvailableChemical IdentifiersUNIINot AvailableCAS numberNot AvailableInChI KeyULDXUWXTVRRUND-SWLSCSKDSA-NInChIInChI=1S/C16H25N3O7S2/c1-3-4-9-26-13-5-7-14(8-6-13)28(24,25)19-11-12(18-27(2,22)23)10-15(19)16(20)17-21/h5-8,12,15,18,21H,3-4,9-11H2,1-2H3,(H,17,20)/t12-,15+/m0/s1IUPAC Name(2R,4S)-1-(4-butoxybenzenesulfonyl)-N-hydroxy-4-methanesulfonamidopyrrolidine-2-carboxamideSMILESCCCCOC1=CC=C(C=C1)S(=O)(=O)N1C[C@H](C[C@@H]1C(=O)NO)NS(C)(=O)=OReferencesGeneral ReferencesNot AvailableExternal LinksPubChem Compound5287415PubChem Substance46506803ChemSpider4449804BindingDB50095567ChEMBLCHEMBL358064ZINCZINC000003870354PDBe Ligand111PDB Entries1g49Clinical TrialsClinical Trials 


PhaseStatusPurposeConditionsCountPharmacoeconomicsManufacturersNot AvailablePackagersNot AvailableDosage FormsNot AvailablePricesNot AvailablePatentsNot AvailablePropertiesStateSolidExperimental PropertiesNot AvailablePredicted PropertiesPropertyValueSourceWater Solubility0.459 mg/mLALOGPSlogP0.2ALOGPSlogP-0.46ChemaxonlogS-3ALOGPSpKa (Strongest Acidic)8.71ChemaxonpKa (Strongest Basic)-4.9ChemaxonPhysiological Charge0ChemaxonHydrogen Acceptor Count7ChemaxonHydrogen Donor Count3ChemaxonPolar Surface Area142.11 Å2ChemaxonRotatable Bond Count7ChemaxonRefractivity101.32 m3·mol-1ChemaxonPolarizability43.62 Å3ChemaxonNumber of Rings2ChemaxonBioavailability1ChemaxonRule of FiveYesChemaxonGhose FilterNoChemaxonVeber's RuleNoChemaxonMDDR-like RuleNoChemaxonPredicted ADMET FeaturesPropertyValueProbabilityHuman Intestinal Absorption+0.9756Blood Brain Barrier-0.6509Caco-2 permeable-0.6781P-glycoprotein substrateSubstrate0.7046P-glycoprotein inhibitor INon-inhibitor0.6823P-glycoprotein inhibitor IINon-inhibitor0.6311Renal organic cation transporterNon-inhibitor0.8827CYP450 2C9 substrateNon-substrate0.6024CYP450 2D6 substrateNon-substrate0.7768CYP450 3A4 substrateSubstrate0.588CYP450 1A2 substrateNon-inhibitor0.8116CYP450 2C9 inhibitorNon-inhibitor0.6106CYP450 2D6 inhibitorNon-inhibitor0.8932CYP450 2C19 inhibitorNon-inhibitor0.6442CYP450 3A4 inhibitorNon-inhibitor0.6055CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8307Ames testNon AMES toxic0.5939CarcinogenicityNon-carcinogens0.7229BiodegradationNot ready biodegradable0.9762Rat acute toxicity2.4873 LD50, mol/kg Not applicablehERG inhibition (predictor I)Weak inhibitor0.9719hERG inhibition (predictor II)Non-inhibitor0.5641  ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397) SpectraMass Spec (NIST)Not AvailableSpectraSpectrumSpectrum TypeSplash KeyPredicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot AvailableTargetsBuild, predict & validate machine-learning modelsUse our structured and evidence-based datasets to unlock newinsights and accelerate drug research.Learn more  Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.Learn moreBinding Properties×PropertyMeasurementpHTemperature (°C)ReferencesIC 50 (nM)16N/AN/AA29906


 Details


 Binding Properties1. Stromelysin-1KindProteinOrganismHumansPharmacological actionUnknownGeneral FunctionZinc ion bindingSpecific FunctionCan degrade fibronectin, laminin, gelatins of type I, III, IV, and V; collagens III, IV, X, and IX, and cartilage proteoglycans. Activates procollagenase.Gene NameMMP3Uniprot IDP08254Uniprot NameStromelysin-1Molecular Weight53976.84 DaReferencesOverington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article] Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article] ×Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice. Learn more   Drug created at June 13, 2005 13:24 / Updated at July 02, 2020 13:15 